Muscarinic Receptors as Model Targets and Antitargets for Structure-Based Ligand Discovery
Authors:
- Andrew C. KruseAKAndrew C. Kruse
- Dahlia R. WeissDWDahlia R. Weiss
- Mario RossiMRMario Rossi
- Jianxin HuJHJianxin Hu
- Kelly HuKHKelly Hu
- Katrin EitelKEKatrin Eitel
- Peter GmeinerPGPeter Gmeiner
- Jürgen WessJWJürgen Wess
- Brian K. KobilkaBKBrian K. Kobilka
- Brian K. ShoichetBSBrian K. Shoichet
- 1 October 2013
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 84 (4) , 528-540
Abstract
G protein–coupled receptors (GPCRs) regulate virtually all aspects of human physiology and represent an important class of therapeutic drug targets. Many GPCR-targeted drugs resemble endogenous agonists, often resulting in poor selectivity among receptor subtypes and restricted pharmacologic profiles. The muscarinic acetylcholine receptor family exemplifies these problems; thousands of ligands are known, but few are receptor subtype–selective and nearly all are cationic in nature. Using structure-based docking against the M2 and M3 muscarinic receptors, we screened 3.1 million molecules for ligands with new physical properties, chemotypes, and receptor subtype selectivities. Of 19 docking-prioritized molecules tested against the M2 subtype, 11 had substantial activity and 8 represented new chemotypes. Intriguingly, two were uncharged ligands with low micromolar to high nanomolar Ki values, an observation with few precedents among aminergic GPCRs. To exploit a single amino-acid substitution among the binding pockets between the M2 and M3 receptors, we selected molecules predicted by docking to bind to the M3 and but not the M2 receptor. Of 16 molecules tested, 8 bound to the M3 receptor. Whereas selectivity remained modest for most of these, one was a partial agonist at the M3 receptor without measurable M2 agonism. Consistent with this activity, this compound stimulated insulin release from a mouse β-cell line. These results support the ability of structure-based discovery to identify new ligands with unexplored chemotypes and physical properties, leading to new biologic functions, even in an area as heavily explored as muscarinic pharmacology.Keywords
This publication has 48 references indexed in Scilit:
- Conformation Guides Molecular Efficacy in Docking Screens of Activated β-2 Adrenergic G Protein Coupled ReceptorACS Chemical Biology, 2013
- ZINC: A Free Tool to Discover Chemistry for BiologyJournal of Chemical Information and Modeling, 2012
- Identification of Novel Adenosine A2A Receptor Antagonists by Virtual ScreeningJournal of Medicinal Chemistry, 2012
- Crystal Structure-Based Virtual Screening for Fragment-like Ligands of the Human Histamine H1 ReceptorJournal of Medicinal Chemistry, 2011
- Computer-aided drug-discovery techniques that account for receptor flexibilityCurrent Opinion in Pharmacology, 2010
- Structure-Based Discovery of A2AAdenosine Receptor LigandsJournal of Medicinal Chemistry, 2010
- Structure-Based Discovery of Novel Chemotypes for Adenosine A2AReceptor AntagonistsJournal of Medicinal Chemistry, 2010
- Automated Docking Screens: A Feasibility StudyJournal of Medicinal Chemistry, 2009
- Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disordersTrends in Pharmacological Sciences, 2009
- Flexible ligand docking to multiple receptor conformations: a practical alternativeCurrent Opinion in Structural Biology, 2008